Timothy D Connors

This inventor holds 14 USPTO granted patents and 4 published patent applications and 2 EPO patents, primarily in Biotechnology Research. Top assignees: Genzyme Corporation, Johns Hopkins University, Sanofi. Active years: 1997-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy D Connors. Retrieved from https://idiyas.com/inventor/timothy-d-connors

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 85.7

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 7.6

ph-index = 5

Forward Citations = 53(Granted Patents)

Location History:

Hopkinton, MA (US) (1997 - 2005)
Shrewsbury, MD (US) (2020)
Shrewsbury, MA (US) (2014 - 2022)

Company Filing History:

Johns Hopkins University

University of Utah Research Foundation

patents

5. 5 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2022

Loading Chart...

Areas of Expertise:

Multispecific Binding Molecules

Anti-CXCR3 Antibodies

Dystroglycan

Laminin-2

KVLQT1 Gene

Long QT Syndrome

Polycystic Kidney Disease

Nucleic Acids

Human Chromosome 16

Genetic Diagnostics

Gene Compositions

Methods of Use

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11254737 - Multispecific binding molecules having specificity to dystroglycan and laminin-2 (2022-02-22),

2. 10626169 - Multispecific binding molecules having specificity to dystroglycan and laminin-2 (2020-04-21),

3. 9765144 - Nucleic acids encoding anti-CXCR3 antibodies (2017-09-19),

4. 8865870 - Anti-CXCR3 antibodies and methods of use thereof (2014-10-21),

5. 6972176 - KVLQT1—a long QT syndrome gene (2005-12-06),

6. 6867288 - Polycystic kidney disease gene (2005-03-15),

7. 6582913 - Diagnostic method for KVLQT1—a long QT syndrome gene (2003-06-24),

8. 6451534 - KVLQT1—a long QT syndrome gene (2002-09-17),

9. 6420124 - KVLQT1—a long qt syndrome gene (2002-07-16),

10. 6277978 - KVLQT1—a long QT syndrome gene (2001-08-21),

11. 6071717 - Polycystic kidney disease gene and protein (2000-06-06),

12. 6030806 - Human chromosome 16 genes, compositions, methods of making and using same (2000-02-29),

13. 6028173 - Human chromosome 16 genes, compositions, methods of making and using same (2000-02-22),

14. 5654170 - Polycystic kidney disease gene (1997-08-05),

Title: Inventor Timothy D. Connors: Pioneering Advances in Multispecific Binding Molecules

Introduction

Timothy D. Connors, based in Hopkinton, Massachusetts, has made remarkable contributions to the field of biotechnology with a notable portfolio of 14 patents. His innovative work primarily focuses on the development of multispecific binding molecules, which have significant implications for medical treatments, particularly in addressing alpha-dystroglycanopathies.

Latest Patents

Connors' latest patent centers on multispecific binding molecules that exhibit specificity to two significant proteins: dystroglycan and laminin-2. This groundbreaking invention comprises a first binding domain that interacts with an extracellular portion of dystroglycan and a second binding domain that binds to laminin-2. These binding molecules offer promising methods for their creation and utilization in treating or preventing alpha-dystroglycanopathies, presenting new avenues for therapeutic interventions.

Career Highlights

Throughout his career, Timothy D. Connors has applied his expertise at various cutting-edge organizations, including Genzyme Corporation. His work has consistently pushed the boundaries of what is possible in biotechnology and has contributed to advancing the scientific understanding and therapeutic potential of complex biological interactions.

Collaborations

Connors has collaborated with notable professionals in the field, including Gregory M. Landes and Timothy C. Burn. These collaborations have fostered innovative thinking and contributed to the successful development of advanced binding molecules that promise to impact patient care positively.

Conclusion

In summary, Timothy D. Connors stands out as an inventive force within biotechnology. His dedication to creating multispecific binding molecules exemplifies the type of innovative thinking that drives progress in the treatment of complex diseases. With his ongoing contributions, Connors continues to pave the way for future advancements in medical therapies.

Profile summary based on public USPTO records.